Big pharma, Partnering

EMD Serono and Pfizer in co-promotion agreement for Xalkori

Posted on 06 May 2015

Tags: ,

EMD Serono has begun co-promoting Pfizer's anaplastic lymphoma kinase (ALK) inhibitor XALKORI (crizotinib) as part of its global strategic alliance with Pfizer.

The initiation of field-based commercialization efforts for XALKORI illustrates the company's dedication to oncology, and to bringing important treatment options for challenging cancers to patients.

This co-promotion relationship is part of the larger, global strategic alliance between Merck KGaA and Pfizer to jointly develop and commercialize avelumab, an investigational anti-PD-L1 monoclonal antibody, to accelerate the development of immuno-oncology medicines for patients with cancer.

The immuno-oncology alliance will also advance Pfizer's PD-1 antibody.


Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
  • CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time


Print Friendly, PDF & Email

Leave a Reply